3-(4-((1-(trans-4-(tert-Butyl)cyclohexyl)-3-(4-(trifluoromethoxy)phenyl)ureido)methyl)benzamido)propanoic acid
- Catalog No. :
- ACMVGL765
- CAS No. :
- 307983-31-9
- Molecular Formula :
- C29H36F3N3O5
- Molecular Weight :
- 563.62
IUPAC Name:3-(4-((1-((1r,4r)-4-(tert-butyl)cyclohexyl)-3-(4-(trifluoromethoxy)phenyl)ureido)methyl)benzamido)propanoic acid
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
2mg99%$53.00Login to see priceIn stockInquiry
5mg99%$95.00Login to see priceInquiryInquiry
10mg99%$144.00Login to see priceInquiryInquiry
Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.
0 Reviews:View Reviews
Product Information
| Product Name | 3-(4-((1-(trans-4-(tert-Butyl)cyclohexyl)-3-(4-(trifluoromethoxy)phenyl)ureido)methyl)benzamido)propanoic acid |
|---|---|
| IUPAC Name | 3-(4-((1-((1r,4r)-4-(tert-butyl)cyclohexyl)-3-(4-(trifluoromethoxy)phenyl)ureido)methyl)benzamido)propanoic acid |
| MDL No. | MFCD11977277 |
| Molecular Formula | C29H36F3N3O5 |
| Molecular Weight | 563.62 |
| SMILES | O=C(O)CCNC(C1=CC=C(CN([C@H]2CC[C@H](C(C)(C)C)CC2)C(NC3=CC=C(OC(F)(F)F)C=C3)=O)C=C1)=O |
| InChI Key | BZXMLCVDKDXRQY-AFARHQOCSA-N |
| Synonym | GRA Ex-25;B-Alanine, N-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]methyl]benzoyl]-;β-Alanine, N-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]methyl]benzoyl]-;GRA Ex-25 USP/EP/BP;GRA Ex-25[GRA-Ex-25;GCGR,inhibit,GRA Ex 25,Inhibitor,GRA Ex-25,Glucagon Receptor,GRA Ex25;3-(4-((1-(trans-4-(tert-Butyl)cyclohexyl)-3-(4-(trifluoromethoxy)phenyl)ureido)methyl)benzamido)propanoic acid;3-{[4-({1-[(1r,4r)-4-tert-butylcyclohexyl]{[4-(trifluoromethoxy)phenyl]carbamoyl}amino}methyl)phenyl]formamido}propanoic acid |
| CAS No. | 307983-31-9 |
| PubChem CID | 16100296 |
Safety Data
- Pictogram
- Signal Word
- Warning
- Hazard Statement(s)
- H302-H315-H319-H335
- Precautionary Statement(s)
- P261-P305+P351+P338
